Real‐World Outcomes of Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiotherapy in Stage II–III Locally Advanced Rectal Cancer: A Comparative Cohort Study
Asia-Pacific Journal of Clinical Oncology · 21.04.2026
DOI: 10.1111/ajco.70118 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, online erschienen am 21.04.2026. Verfasst von Aysun Arslantas Erken und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Health Science, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Aim
Total neoadjuvant therapy has been adopted to improve systemic disease control in locally advanced rectal cancer, yet long‐term real‐world outcomes, particularly in non‐Western populations, remain incompletely defined. We compared total neoadjuvant therapy with neoadjuvant chemoradiotherapy and assessed the prognostic impact of posttreatment lymphovascular and perineural invasion.
Methods
We retrospectively analyzed 171 patients with Stage II–III locally advanced rectal cancer treated between 2016 and 2023 with total neoadjuvant therapy ( n = 76) or neoadjuvant chemoradiotherapy ( n = 95) followed by total mesorectal excision. Overall survival was the primary endpoint; secondary endpoints included disease‐free survival, local recurrence‐free survival, distant metastasis‐free survival, and treatment response.
Results
At a median follow‐up of 45 months, total neoadjuvant therapy was associated with numerically higher 5‐year overall survival than neoadjuvant chemoradiotherapy (74.3% vs 60.0%; hazard ratio 0.58, 95% confidence interval 0.32–1.06; log rank p = 0.048). Disease‐free survival, local recurrence‐free survival, and distant metastasis‐free survival numerically favored total neoadjuvant therapy but did not reach statistical significance. Pathologic complete response occurred in 39.5% versus 30.5% with total neoadjuvant therapy and neoadjuvant chemoradiotherapy, respectively ( p = 0.221), and was associated with improved local recurrence‐free survival and distant metastasis‐free survival. The absence of lymphovascular and perineural invasion predicted favorable outcomes. Adjuvant chemotherapy was more frequently administered after neoadjuvant chemoradiotherapy.
Conclusion
In this real‐world cohort, total neoadjuvant therapy was associated with numerically higher overall survival than neoadjuvant chemoradiotherapy, whereas recurrence‐based endpoints were comparable. Posttreatment lymphovascular invasion and perineural invasion provided clinically informative prognostic stratification beyond response assessment and may help inform postoperative risk assessment in the TNT era.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Health Science, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey.
ORCID-Profile: Aysun Arslantas Erken, Selvi Tabak Dincer
Zitieren
APA
Erken, A. A., & Dincer, S. T. (2026). Real‐World Outcomes of Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiotherapy in Stage II–III Locally Advanced Rectal Cancer: A Comparative Cohort Study. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.70118
Vancouver
Erken AA, Dincer ST. Real‐World Outcomes of Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiotherapy in Stage II–III Locally Advanced Rectal Cancer: A Comparative Cohort Study. Asia-Pacific Journal of Clinical Oncology. 2026. doi:10.1111/ajco.70118
BibTeX
@article{Erken2026,
author = {Erken, Aysun Arslantas and Dincer, Selvi Tabak},
title = {Real‐World Outcomes of Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiotherapy in Stage II–III Locally Advanced Rectal Cancer: A Comparative Cohort Study},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
doi = {10.1111/ajco.70118}
}
EUVIMED